Skip to main content
    N

    Neurosense Therapeutics Ltd (NRSN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.69
    -0.07 (-3.98%)

    Market Cap: $3.21M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Neurosense Therapeutics Ltd (NRSN) Financials: Revenue, Profit and Cash Flow

    Updated Jun 30, 2026. Financial statements from company filings, amounts in US dollars.

    Neurosense Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$11.13M, operating cash flow was -$7.67M and free cash flow was -$7.68M. The quarter ended Dec 31, 2025 had net income of -$3.21M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $11.09M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Dec 2025, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Cost of revenueN/A$22.00K$97.00K$89.00K$3.00K$3.00KN/A
    Gross profitN/A-$22.00K-$97.00K-$89.00K-$3.00K-$3.00KN/A
    Research and development$6.23M$5.70M$7.27M$6.42M$3.08M$2.50M$898.00K
    Operating income-$11.09M-$9.90M-$12.05M-$13.55M-$5.59M-$2.89M-$1.24M
    Net income-$11.13M-$10.21M-$10.11M-$12.34M-$4.04M-$2.83M-$1.23M
    EBITDAN/A-$9.88M-$9.64M-$12.23M-$2.88M-$2.83M$13.00K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Operating income-$3.20M-$3.20M-$2.35M-$2.35M-$1.77M-$2.11M-$3.03M-$2.99M-$3.29M-$2.90M-$3.48M-$2.99M
    Net income-$3.21M-$3.21M-$2.35M-$2.35M-$1.80M-$2.15M-$857.00K-$5.40M-$2.95M$784.00K-$5.22M-$2.92M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $98.00K by $68.00K. Shareholder equity was negative, at -$1.56M, as total liabilities of $2.59M exceeded total assets of $1.03M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$1.03M$4.58M$3.19M$7.71M$11.43M$779.00K$955.00K
    Current assets$778.00K$4.40M$2.92M$7.38M$11.41M$729.00K$913.00K
    Cash and equivalents$166.00K$3.38M$2.64M$3.54M$11.06M$699.00K$895.00K
    Total liabilities$2.59M$1.99M$4.94M$2.09M$2.42M$120.00K$37.00K
    Short-term debt$98.00K$73.00K$69.00K$64.00KN/AN/AN/A
    Shareholder equity-$1.56M$2.58M-$1.76M$5.62M$9.01M$659.00K$918.00K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$896.00K$1.03M$1.03M$1.68M$1.68M$4.58M$984.00K$1.84M$1.45M$3.19M$5.39M$7.87M
    Total liabilities$3.00M$2.59M$2.59M$2.20M$2.20M$1.99M$3.80M$3.54M$8.44M$4.94M$5.58M$9.41M
    Cash and equivalents$231.00K$166.00K$166.00K$666.00K$666.00K$3.38M$344.00K$1.21M$735.00K$2.64M$4.76M$7.09M
    Shareholder equity-$2.10M-$1.56M-$1.56M-$519.00K-$519.00K$2.58M-$2.82M-$1.70M-$6.99M-$1.76M-$196.00K-$1.54M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$7.67M-$10.13M-$8.35M-$7.59M-$1.54M-$695.00K-$582.00K
    Capital expenditures$8.00K$3.00K$29.00K$70.00K$17.00K$9.00K$7.00K
    Free cash flow-$7.68M-$10.14M-$8.38M-$7.66M-$1.56M-$704.00K-$589.00K
    Investing cash flow-$8.00K$1.00K$3.47M-$3.54M-$17.00K-$9.00K-$26.00K
    Financing cash flow$4.43M$10.91M$3.98M$3.69M$11.90M$508.00K$1.42M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Operating cash flow-$1.84M-$1.84M-$2.00K-$2.00KN/AN/AN/AN/AN/AN/A$1.78KN/A
    Capital expenditures$1.50K$1.50K$0$0$0$0$0$0$0$0$0$0
    Free cash flow-$1.84M-$1.84M-$2.00K-$2.00KN/AN/AN/AN/AN/AN/A$1.78KN/A
    Last 12 quarters

    Frequently Asked Questions About NRSN

    What is Neurosense Therapeutics' annual revenue?

    Neurosense Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Neurosense Therapeutics profitable?

    No. Neurosense Therapeutics reported net income of -$11.13M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does NRSN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$7.67M minus capital expenditures of $8.00K produced free cash flow of -$7.68M.

    How much debt does Neurosense Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $98.00K and cash and equivalents of $166.00K.